Edition:
United States

Nivalis Therapeutics Inc (NVLS.OQ)

NVLS.OQ on NASDAQ Stock Exchange Global Market

2.39USD
4:00pm EDT
Change (% chg)

$0.02 (+0.84%)
Prev Close
$2.37
Open
$2.36
Day's High
$2.42
Day's Low
$2.36
Volume
5,333
Avg. Vol
41,181
52-wk High
$9.35
52-wk Low
$2.01

NVLS.OQ

Chart for NVLS.OQ

About

Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company's S-nitrosogl... (more)

Overall

Beta: --
Market Cap(Mil.): $36.79
Shares Outstanding(Mil.): 15.66
Dividend: --
Yield (%): --

Financials

  NVLS.OQ Industry Sector
P/E (TTM): -- 242.00 19.11
EPS (TTM): -2.09 -- --
ROI: -51.83 -8.00 -5.00
ROE: -51.83 -10.45 -4.24

BRIEF-Nivalis Therapeutics enters into merger agreement with Alpine Immune Sciences

* Nivalis Therapeutics reports first quarter 2017 financial results

May 01 2017

BRIEF-Nivalis Therapeutics and Alpine Immune Sciences Inc agree to combine

* Nivalis Therapeutics Inc and Alpine Immune Sciences Inc. Agree to combine

Apr 18 2017

BRIEF-Nivalis Therapeutics announces results from phase 2 clinical trial of Cavosonstat

* Nivalis Therapeutics announces results from phase 2 clinical trial of Cavosonstat added to Ivacaftor for treatment of cystic fibrosis Source text for Eikon: Further company coverage:

Feb 23 2017

BRIEF-Nivalis Therapeutics reports Q4 loss per share of $0.50

* Nivalis Therapeutics reports fourth quarter and full-year 2016 financial results

Feb 13 2017

BRIEF-Nivalis therapeutics announces corporate restructuring

* Nivalis Therapeutics Inc says intends to complete a reduction in force affecting 25 employees

Jan 12 2017

More From Around the Web

Earnings vs. Estimates